American Journal of
Oral Medicine and Radiology

ISSN - 2394-7721

www.mcmed.us/journal/ajomr

Review Article

PHARMACOLOGICAL APPROACHES IN THE MANAGEMENT OF ORAL CANCER: CURRENT TRENDS AND FUTURE DIRECTIONS

Dr. Tamilselvan D*

[1]Surgeon and Urologist, Kilpauk Medical College, Chennai-600010, Tamilnadu, India.

ABSTRACT

Oral cancer, primarily squamous cell carcinoma, remains a significant health challenge globally, with high morbidity and mortality rates. Pharmacological treatment approaches for oral cancer have evolved over the years, with chemotherapeutic agents, targeted therapies, and immunotherapy playing critical roles in the management. Despite advancements, treatment resistance, recurrence, and systemic toxicity continue to limit the effectiveness of conventional therapies. Recent trends in pharmacology have shifted toward personalized medicine, incorporating molecular profiling and targeted drug delivery systems to improve therapeutic outcomes while minimizing adverse effects. This review highlights the current pharmacological strategies in oral cancer treatment, explores innovative drug delivery systems, and discusses emerging therapies such as immune checkpoint inhibitors and gene therapy. It further addresses the future directions in the pharmacological management of oral cancer, focusing on the integration of novel drug combinations, advanced nanocarriers for localized therapy, and the potential role of biomarkers in predicting patient response to treatment. Ultimately, improving survival rates and quality of life for oral cancer patients requires a multidisciplinary approach, combining pharmacological, surgical, and radiotherapy interventions.

Key words:- Oral cancer, pharmacological approaches, squamous cell carcinoma, chemotherapy, targeted therapy.

Access this article online	
Home page: http://www.mcmed.us/journal/ajomr	Quick Response code

Received:15.02.2026	**Revised**:02.03.2026	**Accepted**:13.04.2026

INTRODUCTION

Oral cancer, predominantly squamous cell carcinoma (OSCC), is a major cause of morbidity and mortality worldwide, particularly in regions with high tobacco and alcohol consumption rates. Despite considerable advancements in treatment modalities, including surgery, radiation therapy, and chemotherapy, oral cancer remains a significant health burden due to challenges such as late diagnosis, treatment resistance, and metastasis. The pharmacological management of oral cancer has evolved significantly over the years, with chemotherapeutic agents traditionally being the cornerstone of treatment.

Corresponding Author
Dr. Tamilselvan D

However, the limitations of conventional chemotherapy, including toxicity, resistance, and poor specificity, have spurred the development of novel pharmacological strategies. Targeted therapy, focusing on specific molecular targets involved in the progression of OSCC, has emerged as an alternative to traditional chemotherapies, offering more specificity and fewer side effects. Agents targeting growth factors, cell signaling pathways, and angiogenesis have shown promise in preclinical and clinical trials[1]. Immunotherapy, especially immune checkpoint inhibitors, has further revolutionized the treatment landscape, providing new hope for patients with advanced stages of oral cancer who are resistant to conventional therapies. Despite the potential of these new approaches, their clinical use is

often limited by challenges such as immune resistance, adverse reactions, and the need for biomarker identification to predict patient responses. Furthermore, the introduction of nanotechnology and drug delivery systems has allowed for the development of advanced therapeutic platforms, such as Nano carriers and drug-eluting implants, to deliver chemotherapy and targeted agents directly to the tumor site, reducing systemic toxicity. Nano medicine has shown significant promise in enhancing the bioavailability and targeting efficiency of oral cancer therapies[2]. The future of oral cancer pharmacology is poised to shift toward personalized medicine, where treatments are tailored based on individual genetic profiles and molecular signatures of tumors. Additionally, combination therapies, integrating chemotherapy, targeted therapies, and immunotherapy, hold the potential to overcome treatment resistance and improve long-term survival outcomes. This review will examine the current pharmacological approaches to oral cancer treatment, the emerging therapies, and future directions in the management of this devastating disease, focusing on advancements in targeted and personalized medicine, innovative drug delivery systems, and the promise of immunotherapy in oral cancer management.

Overview of Oral Cancer and Its Global Impact

Oral cancer, primarily characterized by squamous cell carcinoma (OSCC), is a major public health issue globally, accounting for a significant proportion of head and neck cancers. The incidence of oral cancer is disproportionately higher in countries with high rates of tobacco and alcohol use, with men being more commonly affected than women. Early-stage oral cancer is often asymptomatic, which leads to delayed diagnosis and poorer prognosis. Globally, OSCC is the sixth most common cancer, with an estimated 350,000 new cases diagnosed annually. The survival rates for oral cancer remain low due to its tendency to metastasize to regional lymph nodes and distant organs, often complicating treatment efforts. The global impact is compounded by socio-economic factors, where late-stage diagnosis and inadequate access to healthcare are prevalent in low- and middle-income countries. While developed nations have seen advancements in early detection and treatment protocols, the disparities in healthcare access globally remain a challenge[3]. This results in a significant burden on healthcare systems, with long-term treatment costs and rehabilitation post-treatment. The prognosis for oral cancer is heavily influenced by the stage at diagnosis, with survival rates significantly improving when detected early. However, despite improvements in clinical management, mortality remains high, especially in regions where preventive measures, such as tobacco cessation programs and early screening, are not widespread. This global health challenge underscores the need for increased awareness, better diagnostic tools, improved treatment options, and enhanced access to care in underserved populations. The impact of oral cancer is not only physical but also psychological and social, as patients often face challenges related to disfigurement, speech, and eating, leading to a decreased quality of life. Therefore, comprehensive public health strategies aimed at prevention, early detection, and the development of innovative therapies are essential for combating oral cancer worldwide.

Pathophysiology of Oral Cancer: Key Molecular Mechanisms

Oral cancer, particularly squamous cell carcinoma (OSCC), is driven by a complex interplay of genetic, environmental, and molecular factors that contribute to the initiation and progression of malignancy. The pathophysiology of OSCC begins with the accumulation of genetic mutations in the epithelial cells of the oral cavity, often triggered by carcinogenic agents such as tobacco smoke, alcohol, and human papillomavirus (HPV). These environmental factors induce DNA damage, leading to the activation of oncogenes and inactivation of tumor suppressor genes. A hallmark of OSCC is the activation of the epidermal growth factor receptor (EGFR) pathway, which promotes cell proliferation and survival. Mutations in tumor suppressor genes such as TP53 and CDKN2A are frequently observed in OSCC, leading to dysregulated cell cycle progression and resistance to apoptosis. Additionally, the overexpression of cyclooxygenase-2 (COX-2) and matrix metalloproteinase (MMPs) facilitates the invasion of surrounding tissues and the development of metastatic potential[4]. The activation of the PI3K/Akt and MAPK signaling pathways also plays a crucial role in promoting tumor cell survival and resistance to treatment. Epigenetic alterations, including DNA methylation and histone modification, further contribute to the aberrant gene expression seen in OSCC, enhancing tumorigenicity. The immune microenvironment in OSCC is often characterized by an immunosuppressive milieu, where regulatory T cells (Trigs) and myeloid-derived suppressor cells (MDSCs) inhibit effective immune responses against the tumor. Additionally, chronic inflammation, often driven by tobacco and alcohol use, further promotes carcinogenesis by inducing the release of pro-inflammatory cytokines and growth factors. The molecular mechanisms underlying oral cancer are multifaceted and involve complex interactions between genetic mutations, signaling pathways, and the tumor microenvironment. A better understanding of these molecular alterations is critical for developing targeted therapies and improving the prognosis for OSCC patients.

Current Pharmacological Treatments for Oral Cancer

The treatment of oral cancer, particularly squamous cell carcinoma (OSCC), is multifaceted, involving surgery, radiation therapy, and chemotherapy as the primary modalities. The current pharmacological treatments aim to reduce tumor size, prevent metastasis, and alleviate symptoms. Surgery remains the cornerstone of treatment for early-stage OSCC, where the tumor is surgically excised with adequate margins. However, for advanced stages, the role of chemotherapy and radiation becomes critical. Chemotherapy is often used as adjuvant therapy to prevent recurrence or as a neoadjuvant treatment to shrink tumors before surgery. Cisplatin, a platinum-based drug, is the most commonly used chemotherapeutic agent for oral cancer, often in combination with 5-fluorouracil (5-FU) or methotrexate. These chemotherapy agents work by inhibiting DNA synthesis and inducing cell death. Despite their efficacy, chemotherapy drugs often cause significant side effects, including microsites, nausea, and immunosuppression. Radiation therapy, which is frequently combined with chemotherapy, is used for locally advanced tumors or for patients who are not candidates for surgery. The advent of targeted therapies and immunotherapy has introduced new avenues for treatment[5]. Drugs targeting specific molecular pathways, such as the epidermal growth factor receptor (EGFR) inhibitors like cetuximab, have shown promise in improving outcomes for patients with advanced OSCC. Additionally, immune checkpoint inhibitors, such as pembrolizumab and nivolumab, are being explored as part of a new therapeutic strategy for recurrent or metastatic OSCC. These immunotherapies work by enhancing the body's immune response to target and destroy cancer cells. However, despite these advancements, treatment resistance remains a major challenge in oral cancer pharmacology. A significant concern is the development of resistance to chemotherapy and radiation, as well as the emergence of immune evasion mechanisms that limit the effectiveness of immunotherapies. Thus, ongoing research is focused on developing new pharmacological approaches that can overcome these limitations, including the use of combinational therapies and personalized medicine approaches.

Chemotherapy: Standard Agents and New Developments

Chemotherapy has long been a cornerstone of treatment for oral cancer, particularly for advanced squamous cell carcinoma (OSCC). Traditional chemotherapy agents, such as cisplatin, 5-fluorouracil (5-FU), and methotrexate, have shown efficacy in controlling the growth of tumors and preventing metastasis. Cisplatin, a platinum-based drug, is often used as a first-line treatment for OSCC due to its ability to cross-link DNA, leading to the inhibition of DNA replication and eventual cell death. 5-FU, an antimetabolite, interferes with the synthesis of DNA and RNA, while methotrexate inhibits folate metabolism, another critical process in cell division. These agents are typically used in combination to enhance their therapeutic effects and prevent tumor resistance. However, chemotherapy is associated with a range of side effects, such as microsites, myelosuppression, and nephrotoxicity, which limit its use and impact patient quality of life. New developments in chemotherapy for oral cancer are focused on improving the specificity and efficacy of treatment while minimizing side effects[6]. One promising approach is the use of nanoparticle-based drug delivery systems, which can increase the concentration of chemotherapy agents at the tumor site while reducing systemic toxicity. Nano carriers, such as liposomes and dendrimers, have been explored for delivering cisplatin and 5-FU, enhancing their bioavailability and targeting efficiency. Another development in chemotherapy is the exploration of new chemotherapeutic agents and combination therapies.



Figure:1 Current Pharmacological Treatments for Oral Cancer

For example, the use of tyrosine kinase inhibitors (TKIs), which target specific molecular pathways involved in tumor growth, is being investigated in combination with traditional chemotherapy drugs. Additionally, the use of immune-modulating agents, such as immune checkpoint inhibitors, is being studied in conjunction with chemotherapy to improve the overall therapeutic outcome[7]. Despite these advancements, the challenge of chemotherapy resistance remains a significant hurdle. Tumors may develop resistance through various mechanisms, including drug efflux pumps, altered drug metabolism, and changes in DNA repair mechanisms. To address these challenges, ongoing research is focused on identifying biomarkers for predicting treatment response and resistance, as well as developing novel drugs and combination therapies to enhance the effectiveness of chemotherapy in oral cancer.

Immunotherapy: Emerging Approaches in Oral Cancer Management

However, the effectiveness of immunotherapy is often limited by the presence of an immunosuppressive tumor microenvironment, where regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and

cytokines like TGF-β inhibit the immune system's ability to mount an effective anti-tumor response. Another immunotherapeutic strategy involves adoptive cell therapy, where patients' T cells are harvested, modified to recognize tumor antigens, and reinfused into the body to specifically target cancer cells. Furthermore, cancer vaccines, including those targeting HPV-related oral cancers, represent a promising future direction. These vaccines aim to stimulate the immune system to recognize and attack HPV-infected cells, which are a significant cause of oral cancer. Despite the promising outcomes, challenges remain in the clinical application of immunotherapy, including immune-related adverse events, high cost, and the development of resistance[8]. Ongoing research is focused on identifying biomarkers that predict response to immunotherapy, as well as combining immunotherapy with other modalities, such as chemotherapy, targeted therapy, and radiation, to improve clinical outcomes. Immunotherapy represents a promising frontier in oral cancer management, and with continued advancements, it is expected to play an increasingly important role in the treatment of this disease.



Figure: 2 Immunotherapy: Emerging Approaches in Oral Cancer Management

Role of Nanotechnology in Oral Cancer Pharmacotherapy

Nanotechnology has emerged as a promising tool in the pharmacotherapy of oral cancer, offering innovative solutions to enhance drug delivery, improve therapeutic efficacy, and reduce side effects. Nano carriers, such as liposomes, micelles, dendrimers, and nanoparticles, have been extensively researched for their potential to deliver chemotherapeutic agents, immunotherapeutic agents, and targeted molecules directly to oral cancer cells. One of the major challenges in the treatment of oral cancer is the poor bioavailability of drugs at the tumor site due to the rapid metabolism and elimination of chemotherapeutic agents. Nanotechnology-based drug delivery systems address this issue by encapsulating drugs in nanoparticles, allowing for their controlled release at the tumor site. This targeted delivery not only enhances the concentration of the drug at the tumor but also reduces systemic toxicity, thereby minimizing the side effects commonly associated with conventional chemotherapy[9]. Nanoparticles can also be functionalized with specific ligands or antibodies to selectively target tumor cells, further improving the specificity of treatment. In addition to improving drug delivery, nanotechnology plays a key role in enhancing the imaging and diagnostic capabilities in oral cancer. Nanoparticles can be engineered to carry diagnostic agents, such as fluorescent dyes or contrast agents, to aid in the detection and monitoring of tumors. The application of nanotechnology extends beyond chemotherapy; for instance, Nano carriers are being explored for the delivery of RNA-based therapies, such as small interfering RNA (siRNA) and messenger RNA (mRNA), to silence oncogenes or enhance the immune response. Despite the promising potential of nanotechnology in oral cancer therapy, several challenges remain. These include issues related to the stability of nanoparticles in vivo, the potential for immune recognition and clearance, and the complexity of scaling up production for clinical use. Nevertheless, ongoing research in nanotechnology holds great promise for revolutionizing the pharmacological treatment of oral cancer, making it a valuable tool in the fight against this deadly disease.

Challenges in Oral Cancer Drug Delivery Systems

One of the major challenges in the pharmacological treatment of oral cancer is the development of efficient drug delivery systems that can overcome the anatomical and physiological barriers of the oral cavity. The mucosal lining of the oral cavity, which is constantly exposed to saliva, food, and other external factors, presents a major hurdle to the effective delivery of drugs. Additionally, the rapid clearance of drugs from the oral cavity and the presence of an impermeable epithelium limit the bioavailability of many therapeutic agents. Oral cancer cells often exhibit abnormal vasculature, which can lead to poor penetration of drugs into the tumor. Moreover, the presence of the tumor microenvironment, characterized by an acidic pH, hypoxia, and high interstitial pressure, further complicates drug delivery. Conventional oral drug formulations often fail to provide sufficient drug concentrations at the tumor site, leading to suboptimal therapeutic outcomes[10]. In response to these challenges, novel drug delivery systems, such as nanoparticles, liposomes, and hydrogels, have been developed to improve the pharmacokinetics of anticancer drugs and enhance their targeted delivery to oral cancer cells. These systems are designed to encapsulate drugs and protect them from degradation, enabling controlled release over time and improving the drug's bioavailability at the tumor site. Additionally, targeted drug delivery using ligands or antibodies specific to tumor cell receptors offers a more precise approach, minimizing the impact on healthy tissues. Despite the potential of these systems, several issues remain. These include the difficulty in achieving sustained release at the desired site, the potential for toxicity due to accumulation in non-target tissues, and the complexity of formulating these systems for clinical use. Furthermore, the interaction between drug carriers and the immune system may lead to immune clearance, reducing the therapeutic efficacy of the drug. Overcoming these challenges requires continued research into advanced delivery technologies and the development of new biomaterials to improve the targeting, stability, and controlled release of oral cancer therapies.[11]

Barriers to Effective Drug Penetration in Oral Tissues

Effective drug penetration in oral tissues remains one of the primary challenges in oral cancer pharmacotherapy. The oral cavity, including the mucosa and tumor tissues, presents several barriers that hinder the successful delivery of therapeutic agents. One of the most significant obstacles is the anatomical structure of the oral tissues. The oral mucosa is a highly dynamic, stratified squamous epithelium that acts as a physical barrier, limiting the absorption of drugs. This barrier is further complicated by the continuous flow of saliva, which accelerates the clearance of drug molecules from the oral cavity, reducing their contact time with the target cells. In addition, the presence of various oral tissues, such as the hard and soft palate, tongue, and gingiva, with differing permeability, adds to the complexity of drug delivery. Tumors in the oral cavity may also develop a unique microenvironment, with altered blood supply, extracellular matrix composition, and pH levels, which further impairs drug diffusion. The abnormal

vasculature in oral cancer tumors often leads to poor drug perfusion, contributing to inefficient drug penetration[12]. The tumor cells are surrounded by high interstitial fluid pressure, which can restrict the movement of therapeutic agents into the tumor. Furthermore, the presence of cancer-associated fibroblasts and other stromal components creates a physical barrier that hampers the access of drugs to the cancer cells. These challenges necessitate the development of advanced drug delivery strategies that can overcome the physical and physiological barriers of the oral cavity. Recent innovations in nanotechnology, such as the use of nanoparticles and liposomes, have shown promise in enhancing drug penetration. These delivery systems can be engineered to enhance drug solubility, protect the drug from enzymatic degradation, and facilitate cellular uptake. Additionally, the incorporation of permeation enhancers and targeting ligands can improve the penetration of drugs across the mucosal barrier and into the tumor. Despite these advancements, the complexity of oral tissue barriers remains a critical challenge, and further research is required to develop more efficient delivery systems that can achieve better therapeutic outcomes.

Overcoming Resistance in Oral Cancer Treatment

Resistance to treatment is a significant hurdle in the management of oral cancer, particularly squamous cell carcinoma (OSCC), which frequently develops resistance to chemotherapy, radiation, and targeted therapies. Chemo resistance in OSCC is primarily mediated through several mechanisms, including enhanced DNA repair, the activation of anti-apoptotic pathways, and the overexpression of drug efflux pumps such as P-glycoprotein. These mechanisms prevent the accumulation of therapeutic agents within cancer cells, reducing the efficacy of treatment. Similarly, radiation resistance is often attributed to the activation of cellular repair mechanisms that counteract the DNA damage induced by radiation. Moreover, oral cancer cells may develop resistance to targeted therapies, such as epidermal growth factor receptor (EGFR) inhibitors, due to mutations in the receptor or compensatory activation of alternate signaling pathways. To overcome these challenges, several strategies are being explored[13]. Combination therapies, which involve the simultaneous use of chemotherapy, targeted therapy, and immunotherapy, have shown promise in overcoming resistance by targeting multiple pathways involved in tumor growth and survival. Additionally, the development of novel small molecule inhibitors, monoclonal antibodies, and immune checkpoint inhibitors aims to block the key pathways responsible for resistance. Personalized medicine, which tailor's treatment based on the genetic and molecular profile of the tumor, is another promising strategy. By identifying specific mutations and resistance mechanisms, clinicians can select the most effective therapy for individual patients. Furthermore, the use of nanoparticles for drug delivery can help bypass drug efflux pumps and deliver higher concentrations of therapeutic agents directly to the tumor site. While these strategies hold promise, overcoming resistance remains a major challenge in oral cancer treatment. Continued research is needed to better understand the molecular mechanisms of resistance and develop novel therapeutic approaches to improve patient outcomes[14].

Recent Advances in Combination Therapies for Oral Cancer

Combination therapies have become a cornerstone in the treatment of oral cancer, particularly squamous cell carcinoma (OSCC), as they offer a strategy to overcome resistance, enhance therapeutic efficacy, and minimize the side effects associated with individual treatments. Recent advances in combination therapies involve the integration of chemotherapy, targeted therapies, immunotherapy, and radiation, tailored to the molecular characteristics of the tumor. One promising combination approach is the use of chemotherapeutic agents in conjunction with targeted therapies, such as epidermal growth factor receptor (EGFR) inhibitors. The combination of cisplatin or 5-fluorouracil (5-FU) with EGFR inhibitors has shown enhanced efficacy in clinical trials by blocking key signaling pathways involved in tumor proliferation and survival. Additionally, the combination of chemotherapy and immunotherapy has gained significant attention. Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, when combined with chemotherapy, have demonstrated promising results in treating recurrent or metastatic oral cancer. These agents work by inhibiting the PD-1/PD-L1 axis, thereby enhancing the immune response to cancer cells. Combining chemotherapy and immunotherapy may synergistically overcome immune resistance and enhance tumor cell killing[15].

CONCLUSION

The management of oral cancer has seen remarkable progress in recent years, driven by advances in pharmacological therapies and a better understanding of the disease's molecular and genetic underpinnings. Current trends in the pharmacological treatment of oral cancer emphasize a shift from traditional chemotherapy towards more personalized and targeted approaches, reflecting a growing recognition of the need to tailor treatments based on the molecular profile of individual tumors. The integration of targeted therapies, such as EGFR inhibitors, and immunotherapies, including immune checkpoint inhibitors, has opened new frontiers

in treatment, offering improved outcomes for patients with recurrent or metastatic disease. However, despite these advancements, challenges such as treatment resistance, limited drug penetration, and the complex tumor microenvironment persist, underscoring the need for further innovation in drug delivery systems. Nanotechnology, with its potential for targeted drug delivery, offers an exciting avenue to overcome some of these barriers by enhancing drug bioavailability and minimizing systemic toxicity. Moreover, combination therapies, which involve the synergistic use of chemotherapy, targeted agents, and immunotherapies, are showing promise in overcoming resistance mechanisms and improving overall therapeutic efficacy. The future of oral cancer pharmacology lies in continued advancements in personalized medicine, where therapies are tailored to the genetic and molecular profiles of individual tumors, and the development of new strategies to overcome resistance to treatment. Further research into the tumor microenvironment, drug delivery systems, and the molecular mechanisms of resistance will be critical in refining these approaches.

REFERENCES

1. R. S., Rajendiran, D., R. S., & S. S. (2024). Therapeutic strategies in oral cancer: A review. *Research Journal of Pharmacy and Technology*, 1398–1402.
2. Yang, X., Wang, Y., Yang, Y., Zhang, S., Wang, D., Luo, Y., et al. (2025). Immunostimulatory DNA tetrahedron-based nanovaccine combined with immune checkpoint PD-1 blockade for boosting systemic immune responses against oral squamous cell carcinoma. *Aggregate, 6*.
3. De Melo Cardoso, D., Nogueira, R. M. P., Duarte, G. D., De Faria Cocato, A. C., Ribeiro, D. T. C., Barbosa, P. G., et al. (2025). Oral cancer in women: Clinical profile, risk factors, treatment outcomes and survival predictors in 32 years of experience. *Clinical Oral Investigations, 30*, 7.
4. Uddin, S., Singh, A., Mishra, V., Agrawal, N., Gooi, Z., & Izumchenko, E. (2022). Molecular drivers of oral cavity squamous cell carcinoma in non-smoking and non-drinking patients: What do we know so far? *Oncology Reviews, 16*, 549.
5. Mohamad, I., Glaun, M. D. E., Prabhash, K., Busheri, A., Lai, S. Y., Noronha, V., et al. (2023). Current treatment strategies and risk stratification for oral carcinoma. *American Society of Clinical Oncology Educational Book, 43*, e389810.
6. Belloni, A., Campagna, R., Notarstefano, V., Pozzi, V., Orilisi, G., Pompei, V., et al. (2025). Deepening cisplatin sensitivity on oral squamous cell carcinoma cell lines after PON2 knockdown: A FTIRM investigation. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 330*, 125726.
7. Onagun, Q., & Stephen, K. (2024). Nanotechnology-based drug delivery systems for chemotherapy: A review of current approaches and future prospects. *World Journal of Advanced Research and Reviews, 24*, 1383–1393.
8. Bear, A. S., Fraietta, J. A., Narayan, V. K., O'Hara, M., & Haas, N. B. (2021). Adoptive cellular therapy for solid tumors. *American Society of Clinical Oncology Educational Book, 41*, 57–65.
9. Zhang, Y., Wu, Y., Du, H., Li, Z., Bai, X., Wu, Y., et al. (2023). Nano-drug delivery systems in oral cancer therapy: Recent developments and prospective. *Pharmaceutics, 16*, 7.
10. Zhang, M., Liang, J., Yang, Y., Liang, H., Jia, H., & Li, D. (2020). Current trends of targeted drug delivery for oral cancer therapy. *Frontiers in Bioengineering and Biotechnology, 8*, 618931.
11. Sengar, A. (2025). The role of nanotechnology in revolutionizing cancer treatment. *Preprints.org*.
12. Iwamoto, S., Nishiyama, M., Kawasaki, M., Morito, S., Sakumoto, T., Toda, S., et al. (2023). Oral-specific microenvironments regulate cell behavior and anticancer drug sensitivity of tongue squamous cell carcinoma. *Human Cell, 36*, 643–656.
13. Cheng, Y., Li, S., Gao, L., Zhi, K., & Ren, W. (2021). The molecular basis and therapeutic aspects of cisplatin resistance in oral squamous cell carcinoma. *Frontiers in Oncology, 11*, 761379.
14. Mishra, R. (2023). Treatment failure shortcomings, possible causes and upcoming phyto-optimism in oral cancer. *TABCJ*, 4–27.
15. Ingole, S. G., Aher, A. A., & Thitame, S. N. (2025). Advancements in targeted therapy for oral cancer: A mini review. *Journal of Pharmacy & Bioallied Sciences, 17*, S49–S5.

Cite this article:
Dr. Tamilselvan D. Mucormycosis – Pharmacological Approaches in the Management of Oral Cancer: Current Trends and Future Directions. *American Journal of Oral Medicine and Radiology*, 13(1), 2026, 01-09.